[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100614365":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":10,"centralContacts":19,"locations":29,"responsibleParty":47,"collaborators":10,"id":49,"slug":10,"hasResults":50,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":10,"eligibilityCriteria":54,"healthyVolunteers":50,"sex":55,"minAge":56,"maxAge":10,"enrollmentInfo":57,"targetDuration":10,"studyType":60,"phases":10,"briefSummary":61,"conditions":62,"keywords":64,"overallStatus":68,"whyStopped":10,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":73,"completionDateStruct":75,"leadSponsor":77,"locationsCount":78},{"fullName":5,"class":6},"Consorci Sanitari de l'Alt Penedès i Garraf","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Anticoagulant therapy",null,"Patients who has been discharged from hospital with anticoagulant therapy",[13],"Other: Antithrombotic therapy",[15],{"type":6,"name":16,"description":17,"armGroupLabels":18,"otherNames":10},"Antithrombotic therapy","Anticoagulant treatment prescribed at discharge from an acute care unit",[9],[20,25],{"name":21,"role":22,"phone":23,"phoneExt":10,"email":24},"Mar Saavedra","CONTACT","0034938960025","msaavedra@csapg.cat",{"name":26,"role":22,"phone":23,"phoneExt":27,"email":28},"Noemí Casaponsa","43197","recerca@csapg.cat",[30],{"facility":31,"status":10,"city":32,"state":33,"zip":34,"country":35,"cosmosGeoPoint":36,"geoPoint":41,"contacts":42},"Hospital de Vilafranca","Vilafranca del Penedès","Barcelona","08720","Spain",{"type":37,"coordinates":38},"Point",[39,40],1.69713,41.34618,{"lat":40,"lon":39},[43,44,45],{"name":21,"role":22,"phone":23,"phoneExt":10,"email":24},{"name":26,"role":22,"phone":23,"phoneExt":27,"email":28},{"name":21,"role":46,"phone":10,"phoneExt":10,"email":10},"PRINCIPAL_INVESTIGATOR",{"type":48,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100614365",false,"NCT07278648","High-risk Antithrombotic Drugs at Discharge and Consultation for Hemorrhagic or Thromboembolic Events in the Emergency Department","Prescription of High-risk Antithrombotic Drugs at Discharge and Consultation for Hemorrhagic or Thromboembolic Events in the Emergency Department. Retrospective Cohort Study","Inclusion Criteria:\n\n* Patients discharged from the Emergency Department (ED) and acute care units with an electronic prescription for at least one anticoagulant medication (new or ongoing), identified with the following codes:\n\nB01AA - Vitamin K antagonists: warfarin and acenocoumarol\n\nB01AB - Heparin group: low-molecular weight heparins such as enoxaparin, tinzaparin, bemiparin, …\n\nB01AE - Direct thrombin inhibitors: dabigatran\n\nB01AF - Direct factor Xa inhibitors: rivaroxaban, apixaban, edoxaban\n\nExclusion Criteria:\n\n* Those who are not part of the CSAPG healthcare area.\n* Patients discharged from outpatient clinics, home hospitalization units, intermediate care, or residential facilities.","ALL","18 Years",{"count":58,"type":59},150,"ESTIMATED","OBSERVATIONAL","This observational study aims to estimate the proportion of patients discharged from a hospital with a prescription for anticoagulant medication who subsequently visit the emergency department due to an adverse thrombotic or hemorrhagic event related to the treatment.",[63],"Acute Disease",[65,66,67],"Antithrombotic Treatment","Hemorragic Event","Anticoagulants","NOT_YET_RECRUITING","2025-12-18",{"date":71,"type":72},"2025-12-24","ACTUAL",{"date":74,"type":59},"2026-02-05",{"date":76,"type":59},"2026-03-01",{"name":5,"class":6},1]